IL-6: from its discovery to clinical applications.

By T. Kishimoto. International Immunology, 2010

830 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/d3ef7a1120b74b956908004c69b4ed54f0ba06a7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

In Immunology

Citations in the corpus

Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. (2014, background): “In contrast, a soluble form of gp130 functions as an anti-inflammatory decoy receptor, blocking sIL-6R trans-signalling [53].”
Phenotypic and functional specialization of FOXP3+ regulatory T cells (2011, background): “IL-6 is a widely expressed cytokine with multiple functions that can have a profound influence on T Reg cell development and activit”
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. (2014, background): “For example, elevated IL-6 levels were reported in serum and synovial tissues of patients with RA, as well as in serum in other inflammatory diseases such as Castleman disease and Crohn's disease (Kishimoto, 2010).”
IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. (2011, methodology): “inflammatory activity upon blockade of the IL-6R using a neutralizing monoclonal antibody [109].”
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. (2011, background): “Biologics are now emerging that target these cytokines (e.g., IL-6R blockade by tocilizumab), and selective small molecule JAK inhibitors (e.g., tofacitinib, ruxolitinib) also show favorable phase IIa efficacy in patients with rheumatoid arthritis (5–8).”
Inflammatory markers in population studies of aging (2010, neutral): “2004) Castleman’s disease (Kishimoto 2010) polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) (Goronzy and Weyand 2002; MartinezTaboada, Alvarez et al.”